Pieris Pharmaceuticals and AstraZeneca Strike up to $2.1 Billion Collaboration on Anticalin-based Inhaled Treatments for Respiratory Diseases

Ambrogio Visconti
Tagged:

Goodwin represented Pieris Pharmaceuticals in its strategic collaboration with AstraZeneca to develop novel inhaled drugs that leverage Pieris’ Anticalin® platform. AstraZeneca will make an upfront and…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here